Targeting the ASB3-CPT1A axis-a new player in combating metabolic dysfunction-associated steatotic liver disease

Yueying Yang1,2, Ying Yang1, Yan Lu2

  • 1Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai Clinical Center for Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai 200233, China.

Abstract

No abstract available in PubMed .